Is There More Upside Ahead For Allogene Therapeutics Inc (NASDAQ: ALLO)

Allogene Therapeutics Inc (ALLO) concluded trading on Wednesday at a closing price of $4.15, with 4.08 million shares of worth about $16.92 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -6.95% during that period and on Wednesday February 7 the price saw a gain of about 0.97%. Currently the company’s common shares owned by public are about 144.44M shares, out of which, 103.88M shares are available for trading.

According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 22 times over the past 12 months. They bought 6,234,994 shares in 16 of the transactions. In 6 selling transactions, insiders dumped 103,198 shares.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

However, the stock later moved at a day high price of 4.1900, or with a gain of 0.97%. Stock saw a price change of 17.90% in past 5 days and over the past one month there was a price change of 32.59%. Year-to-date (YTD), ALLO shares are showing a performance of 29.28% which decreased to -45.89% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.23 but also hit the highest price of $7.76 during that period. The average intraday trading volume for Allogene Therapeutics Inc shares is 3.13 million. The stock is currently trading 22.31% above its 20-day simple moving average (SMA20), while that difference is up 36.52% for SMA50 and it goes to 2.32% higher than SMA200.

Allogene Therapeutics Inc (NASDAQ: ALLO) currently have 144.44M outstanding shares and institutions hold larger chunk of about 62.53% of that.

The stock has a current market capitalization of $698.36M and its 3Y-monthly beta is at 0.73. It has posted earnings per share of -$2.24 in the same period. It has Quick Ratio of 12.58 while making debt-to-equity ratio of 0.17. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALLO, volatility over the week remained 9.82% while standing at 7.84% over the month.

Analysts are in expectations that Allogene Therapeutics Inc (ALLO) stock would likely to be making an EPS of -$0.45 in the current quarter, while forecast for next quarter EPS is -$0.44 and it is -$1.76 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.62 which is -$0.34 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.66 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 13.40% while it is estimated to increase by 12.87% in next year.

Most Popular

Related Posts